tacrolimus and Telangiectasia--Hereditary-Hemorrhagic

tacrolimus has been researched along with Telangiectasia--Hereditary-Hemorrhagic* in 2 studies

Reviews

1 review(s) available for tacrolimus and Telangiectasia--Hereditary-Hemorrhagic

ArticleYear
Future treatments for hereditary hemorrhagic telangiectasia.
    Orphanet journal of rare diseases, 2020, 01-07, Volume: 15, Issue:1

    Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000-8000 individuals worldwide. This rare disease is characterized by various vascular defects including epistaxis, blood vessel dilations (telangiectasia) and arteriovenous malformations (AVM) in several organs. About 90% of the cases are associated with heterozygous mutations of ACVRL1 or ENG genes, that respectively encode a bone morphogenetic protein receptor (activin receptor-like kinase 1, ALK1) and a co-receptor named endoglin. Less frequent mutations found in the remaining 10% of patients also affect the gene SMAD4 which is part of the transcriptional complex directly activated by this pathway. Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, recent progress has been made using drugs that target VEGF (vascular endothelial growth factor) and the angiogenic pathway with the use of bevacizumab (anti-VEGF antibody). Furthermore, several exciting high-throughput screenings and preclinical studies have identified new molecular targets directly related to the signaling pathways affected in the disease. These include FKBP12, PI3-kinase and angiopoietin-2. This review aims at reporting these recent developments that should soon allow a better care of HHT patients.

    Topics: Bevacizumab; Drug Repositioning; High-Throughput Screening Assays; Humans; Smad4 Protein; Tacrolimus; Telangiectasia, Hereditary Hemorrhagic; Vascular Malformations

2020

Other Studies

1 other study(ies) available for tacrolimus and Telangiectasia--Hereditary-Hemorrhagic

ArticleYear
Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology.
    Human molecular genetics, 2017, 12-15, Volume: 26, Issue:24

    Hereditary hemorrhagic telangiectasia (HHT) is a highly debilitating and life-threatening genetic vascular disorder arising from endothelial cell (EC) proliferation and hypervascularization, for which no cure exists. Because HHT is caused by loss-of-function mutations in bone morphogenetic protein 9 (BMP9)-ALK1-Smad1/5/8 signaling, interventions aimed at activating this pathway are of therapeutic value. We interrogated the whole-transcriptome in human umbilical vein ECs (HUVECs) and found that ALK1 signaling inhibition was associated with a specific pro-angiogenic gene expression signature, which included a significant elevation of DLL4 expression. By screening the NIH clinical collections of FDA-approved drugs, we identified tacrolimus (FK-506) as the most potent activator of ALK1 signaling in BMP9-challenged C2C12 reporter cells. In HUVECs, tacrolimus activated Smad1/5/8 and opposed the pro-angiogenic gene expression signature associated with ALK1 loss-of-function, by notably reducing Dll4 expression. In these cells, tacrolimus also inhibited Akt and p38 stimulation by vascular endothelial growth factor, a major driver of angiogenesis. In the BMP9/10-immunodepleted postnatal retina-a mouse model of HHT vascular pathology-tacrolimus activated endothelial Smad1/5/8 and prevented the Dll4 overexpression and hypervascularization associated with this model. Finally, tacrolimus stimulated Smad1/5/8 signaling in C2C12 cells expressing BMP9-unresponsive ALK1 HHT mutants and in HHT patient blood outgrowth ECs. Tacrolimus repurposing has therefore therapeutic potential in HHT.

    Topics: Activin Receptors, Type II; Animals; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Gene Expression Profiling; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Loss of Function Mutation; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Signal Transduction; Smad Proteins; Tacrolimus; Telangiectasia, Hereditary Hemorrhagic; Transcriptome; Vascular Endothelial Growth Factor A

2017